Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
Anetta Undas1,2, Leszek Drabik2,3
¹Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
²John Paul II Hospital, Krakow, Poland
³Department of Pharmacology, Jagiellonian University Medical College, Krakow, Poland
Prof. Anetta Undas, MD, PhD, Institute of Cardiology, Jagiellonian University Medical College
80 Prądnicka Street, 31-202 Kraków, Poland, E-mail: firstname.lastname@example.org
The management of atrial fibrillation (AF) in patients who have undergone percutaneous coronary intervention (PCI) with stent implantation is challenging. Oral anticoagulation has been shown to significantly reduce the risk of stroke in AF, whereas dual antiplatelet therapy prevents major adverse cardiovascular events, including stent thrombosis after PCI. A typical triple antithrombotic therapy, involving an anticoagulant, i.e. vitamin K antagonist (VKA), together with aspirin and P2Y12 inhibitor, usually clopidogrel, has been shown to minimize ischemic and stroke risks, but is associated with increased risk of major bleeding. The use of dabigatran, rivaroxaban, or apixaban in combination with antiplatelet agents lowers the risk of major bleeding and makes it an option preferred over triple therapy in the majority of PCI patients with AF. The consistency across randomized controlled trials on combination therapy with non-vitamin K antagonist oral anticoagulant (NOAC) and clopidogrel, including patients with acute coronary syndromes, led to changes in everyday practice. However, the use of triple and dual antithrombotic therapy at high bleeding risk should be individualized. The present review summarizes available data on the efficacy and safety of antithrombotic therapy in AF patients undergoing PCI in the era of NOAC.
ISSUE: CARDIOLOGIA HUNGARICA | 2020 | VOLUME 50, ISSUE 4
The estimates show that up to 15% of atrial fibrillation (AF) patients will require percutaneous coronary intervention with stent implantation (PCI) during their lifetime (1). The most frequent indication for double or triple antithrombotic therapy (DAT, TAT), including a P2Y12 inhibitor with or without aspirin and an oral anticoagulant (OAC), is an acute coronary syndrome (ACS) with concomitant AF, mechanical heart valves, left ventricular thrombus, or recent venous thromboembolism (2). Decision making on the length and intensity of antithrombotic therapy in patients with AF and PCI is based on the predicted risk of thromboembolism and bleeding. Traditionally TAT involving vitamin K antagonist (VKA), mostly warfarin, aspirin and clopidogrel was administered for 6–12 months to reduce the risk of stroke (with VKA) and coronary thrombotic events (with antiplatelet drugs) (3). Available data clearly showed that TAT is associated with a very high risk of bleeding compared with DAT therapy reduced to an oral anticoagulant and a single antiplatelet agent. The 30-day bleeding rates in patients with TAT, including VKA, reaches 2.2%, growing to 12% in one-year follow-up (4), worsening prognosis. Major bleeding in patients with ACS is associated with a fivefold higher risk of death within 30 days (5). High-quality randomized controlled trials (RCTs) providing direct comparisons between diverse DAT and TAT regimens suggest the superiority of DAT after an initial short-period treatment with TAT for the majority of patients with AF undergoing PCI (6–9).
Oral anticoagulants in atrial fibrillation
OAC in AF patients reduces the risk of stroke and systemic thromboembolism (SE) by more than 60% demonstrating superiority over aspirin monotherapy or clopidogrel-based dual antiplatelet therapy (DAPT) (10). Non-vitamin K antagonist oral anticoagulants (NOAC) including apixaban, edoxaban, dabigatran and rivaroxaban, are recommended in preference to VKAs in patients with nonvalvular AF. In a meta-analysis of seminal phase 3 AF RCTs, NOACs reduced all-cause mortality, the risk of stroke or SE and intracranial bleeding by 10, 19% and 52% respectively, but increased gastrointestinal (GI) bleeding risk by one quarter compared with warfarin (11). An increase in GI bleeds on NOACs was driven mainly by results of seminal RCTs evaluating dabigatran and rivaroxaban. Nevertheless, reduction in bleeding-related mortality (relative risk, RR: 0.54, 95%; CI: 0.44–0.67) for all NOACs as compared with warfarin has been demonstrated (12).
Dual antiplatelet therapy after PCI
There is consensus on a 6-month DAPT after PCI for stable angina. A shorter (1-3 months) duration of DAPT should be considered in patients at high bleeding and low ST risk. In patients after ACS, European Society of Cardiology (ESC) guidelines recommend default 12-month DAPT and shorter its duration may be considered among those at high bleeding risk (13, 14. High-risk features for ST that may be precipitated by too early discontinuation of DAPT, include stenting of the left main artery, or proximal left anterior descending artery or last remaining patent artery, suboptimal stent deployment, large stent length (>60 mm), PCI of the bifurcation with two stents implanted, treatment of chronic total occlusion and previous ST, diabetes mellitus and chronic kidney disease (2, 15). Prolonging DAPT duration may substantially reduce the risk of ischemic events in high-risk populations. It has been found that the therapy with clopidogrel, ticagrelor or prasugrel extended beyond 12 months is associated with reduced ischemic events and ST but increased bleeding complications with no change in the mortality rate. The greatest benefit of long-term DAPT with ticagrelor 60 mg b.i.d. has been observed in high-risk post-myocardial infarction (MI) patients with diabetes, multivessel coronary artery disease, and peripheral artery disease (16).
Randomized trials on combination anticoagulant and antiplatelet therapy
Several RCTs have compared TAT with DAT in AF patients undergoing coronary stenting. Early moderate-size studies focused on the efficacy and safety of shortening VKA-based TAT, with the largest impact of the WOEST and ISAR-TRIPLE trials.
The WOEST trial (What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing) compared TAT (VKA + clopidogrel + ASA) with DAT (VKA + clopidogrel) in patients undergoing PCI who required OAC due to AF, mechanical heart valve and other reasons, e.g. apical aneurysm, pulmonary embolism, peripheral artery disease. Bleeding episodes were almost 3-fold lower in the DAT group (hazard ratio, HR: 0.36, 95% CI: 0.26–0.50). In the WOEST trial, only 69% of patients in the TAT group had AF, and 69% of participants in this study used a 12-month TAT compared with other studies (4).
The ISAR-TRIPLE trial (Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation) evaluated shorten the duration of clopidogrel therapy from 6 months to 6 weeks in 614 patients receiving VKA who underwent PCI (one-third with ACS). The primary composite end-point of death, MI, ST, ischemic stroke or Thrombolysis in Myocardial Infarction (TIMI) major bleeding at 9 months, did not differ between the 6-week and 6-month (HR: 1.14, 95% CI: 0.68–1.91) (17). Although WOEST and ISAR-TRIPLE studies were underpowered, shortening of TAT emerged as a safe option in patients with AF and ACS and/or an elective PCI. Based on results of the WOEST and ISAR-TRIPLE studies, the 2015 ESC guidelines for the management of ACS in patients presenting without persistent ST-segment elevation recommended shortening TAT duration in patients at high bleeding risk to one month, irrespective of the stent type (13).
The introduction of the NOACs has added to the complexity of treatment decisions in AF patients, but showed new opportunities increasing the safety of anticoagulant patients. Until now, 4 large RCTs compared the risk-to-benefit ratio of warfarin and the NOACs in combination with antiplatelets (Table 1).
The PIONEER AF-PCI trial (an open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention) tested two lower rivaroxaban doses (15 mg o.d. plus P2Y12 inhibitor for 12 months and 2.5 mg b.i.d. plus DAPT for 1, 6, or 12 months) versus VKA plus DAPT for 1, 6, or 12 months. The TIMI major bleeding was lower in the two groups receiving rivaroxaban (HR: 0.59, 95% CI: 0.47–0.76; HR 0.63, 95% CI: 0.50–0.80; respectively) compared with the TAT group. There was no difference in all-cause death, death from cardiovascular causes, MI, or stroke between the three groups (7).
The REDUAL-PCI trial (A Prospective Randomised, Open Label, Blinded Endpoint Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110 mg and 150 mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 – 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation That Have Undergone a Percutaneous Coronary Intervention With Stenting) which assessed DAT (dabigatran 110 mg bid or 150 mg bid and a P2Y12 inhibitor, mostly clopidogrel) with TAT (warfarin and clopidogrel and ASA), showed a reduction of major and non-major bleeding events in the DAT group with 110 mg dabigatran (HR: 0.52, 95% CI: 0.42–0.63) and the DAT group with 150 mg dabigatran (HR: 0.72, 95% CI: 0.58–0.88) compared with TAT. There was no difference in ischemic complications and death between DAT and TAT strategy (8).
The AUGUSTUS trial (An Open-label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention),the largest trial to date on combined antithrombotic therapy in AF patients undergoing PCI, showed that apixaban 5 mg b.i.d. reduces the risk of major bleeding or clinically relevant non-major (CRNM) bleeding compared with VKA (HR: 0.69, 95% CI: 0.58–0.81). Of note, aspirin compared with placebo was associated with higher bleeding risk (HR: 1.89, 95% CI: 1.59–2.24). The safest combination therapy apixaban with P2Y12 involving inhibitor (predominantly clopidogrel) with 16.8 bleeding events /100 patients-years observed vs 49.1 events /100 patients-years in the group with VKA + aspirin + P2Y12 inhibitor (9).
The ENTRUST-AF PCI trial (Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen in subjects with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement, n=1506) demonstrated edoxaban 60 mg o.d. + P2Y12 inhibitor for 12 months to be non-inferior to VKA + P2Y12 inhibitor + aspirin (100 mg once daily, for 1–12 months) regarding major or CRNM bleeding events (HR 0.83, 95% CI 0.65–1.05) (6).
There is strong evidence from several meta-analyses that in patients with AF undergoing PCI, antithrombotic regimens involving a VKA with DAPT should be generally avoided, whereas the use of a NOAC with a P2Y12 inhibitor without aspirin remains the best option 19).
In the most recent systematic review of five RCTs for patients with AF undergoing PCI (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI, n=11,542) a lower bleeding risk, without a reduction in antithrombotic effectiveness was observed for regimens in which aspirin was discontinued (20). TIMI major bleeding was lower for NOAC plus P2Y12 inhibitor (RR: 0.52, 95% CI: 0.35–0.79) and VKA plus P2Y12 inhibitor (RR: 0.57, 95% CI: 0.31–1.00), with no difference for NOAC plus DAPT (RR: 0.69, 95% CI: 0.40–1.16) as compared with VKA plus DAPT. Major adverse cardiovascular events, including MI and ST, did not differ between DAT, NOAC plus DAPT and VKA plus DAPT regimen as a reference (Figure 1).
Controversial issues regarding TAT
Findings across studies on DAT and TAT in patients with AF and PCI may be affected by different regimens of NOACs, and P2Y12 inhibitors, different doses of NOACs and open-label trial design. Seminal trials were largely underpowered for differences in rare events as the incidence of MI, ST, and ischemic stroke. Moreover, major adverse cardiac events (MACE) definition varied among studies. A composite end-point included MI, ST, and stroke in all 4 studies, all-cause death (RE-DUAL PCI, AUGUSTUS), cardiovascular death (PIONEER-AF PCI and ENTRUST-AF PCI) urgent/unplanned revascularization in the RE-DUAL PCI and AUGUSTUS trials. However, as for the ischemic events, there was a clear trend towards a higher number of MI and ST with DAT vs. TAT in all 4 trials, and some meta-analyses showed statistically significantly higher rates of MI and/or ST with DAT vs. TAT (21, 22). This observation was mainly driven by studies with reduced dose NOACs, especially with dabigatran 110 mg b.i.d. Some meta-analysis suggested that the likelihood of an excess of thromboembolic events during DAT vs. TAT was low (23). Lower bleeding risk with DAT compared with TAT was seen regardless of the used bleeding scale, i.e., TIMI bleeding scale in the PIONIER – AF trial versus International Society on Thrombosis and Haemostasis (ISTH) bleeding classifications in other studies.
Optimal TAT duration before DAT and timing of aspirin cessation post an ACS or elective PCI remain unknown. Seminal trials on a combination of antithrombotic agents in patients with AF undergoing PCI have included a large proportion of patients with ACS (38.8–61.5%) who have higher ST risk compared with those undergoing elective PCI. A peri-procedural period of TAT was ranging from 3 days (PIONIER-AF) to 14 days after PCI (AUGUSTUS). Half of the patients in TAT groups of the PIONEER AF-PCI trial continued DAPT for 12 months without a difference in major bleeding or transfusion rates between the NOAC + DAPT and VKA + DAPT groups (15).
The optimal P2Y12 inhibitor in ACS or elective PCI in combined therapy remains to be established. Most studies on DAT and TAT were conducted with clopidogrel, supporting its use in combination therapy. In contrast, there is currently limited evidence to support the use of OACs with ticagrelor or prasugrel in DAT after PCI as an alternative to TAT. The routine use of ticagrelor or prasugrel in TAT is contraindicated, however, based mainly on the results of the RE-DUAL-AF where 12% of patients were treated with ticagrelor (n=327), the 2019 ESC guidelines on chronic coronary syndromes recommended DAT with ticagrelor or prasugrel in patients with a moderate-to-high risk of ST (Class IIb, level of evidence C, Table 2) (2). The North American consensus statement on antithrombotic therapy in patients with AF undergoing PCI makes DAT with ticagrelor but not prasugrel as an option for patients with high ischemic and low bleeding risk (24). Other strategies to decrease bleeding risk during DAT and TAT include adding a proton pump inhibitor and avoiding nonsteroidal anti-inflammatory agents; however, these strategies were not tested in RCTs.
Observational studies on antithrombotic therapy following PCI in anticoagulated AF patients largely reported findings similar to RCTs. Sindet-Pedersen et al. (25), based on the Danish nationwide registry (n=3222), showed for 3- and 12-month TAT with NOAC, a 1.94% and 4.50% decrease in absolute major bleeding risk and similar thromboembolic protection, as compared with TAT with VKA. Of note, DAT with NOAC, when compared with DAT with VKA, resulted in lower absolute risk of MI (–1.53% and –2.99% at 3 and 12 months, respectively) with no significant difference in major bleeding, stroke and all-cause mortality. In 2015 a European Heart Rhythm Association Survey showed that most centers preferred VKA over NOACs in TAT after PCI in AF patients with 12% preferring NOAC. Over 70% of centers used TAT therapy with aspirin (75–100 mg/day) and clopidogrel (75 mg/day) for 3 months followed by 3-6 months of DAT in patients with a DES and AF. Nearly half of the centers considered bare-metal stents in case of MI in the group at high bleeding risk and two-thirds in elective PCI (26).
Antithrombotic therapy in specific subgroups
There are limited data on the combined antiplatelet and anticoagulant therapy safety, in particular, AF patient subsets, including the elderly, underweight or obesity, patients with cancer, chronic kidney disease, liver injury, thrombocytopenia, and ST (1, 3).
The greater risk of bleeding in older patients with AF makes combined antithrombotic therapy challenging. It appears that in the group above 75 years, similar to the younger subjects, NOAC reduced risk of ICB but increased GI bleeds compared with VKA (11). In RCTs, apixaban was the only NOAC that showed a reduction of major bleeding among older patients compared with VKA (27). Four large RCTs comparing warfarin and the NOACs in combination with antiplatelets, showed a significant reduction of 35% in major bleeding for DAT (28). The mean age of study participants was 69.9 and 70.8 years, while the elderly constituted 22.9% and 34% (RE-DUAL PCI trial and PIONEER AF-PCI study, respectively) (7, 8). In the Spanish study on patients aged ≥75 years with AF undergoing PCI, TAT as compared with DAPT, was associated with a lower rate of thromboembolism (0.6% vs. 6.9%) and a higher rate of major bleeding (11.7% vs. 2.4%, respectively) (28).
Underweight or obesity
The bleeding risk of antiplatelets, particularly prasugrel, was markedly increased in underweight patients (13). Low body weight may increase NOAC exposure and increase the risk of bleeding (29). Post hoc analyses of RCTs showed similar efficacy and safety of dabigatran in patients with body weight below 50 kg, whereas observational studies suggested higher bleeding risk. Apixaban, for which body weight ≤60 kg (together with age ≥80 years and/or creatinine ≥1.5 mg/dL) is a dose-reduction criterion, was safer than warfarin in the underweight patients (30). To our knowledge, there have been no outcome data for rivaroxaban use in patients <60 kg published to data.
Obesity may enhance platelet reactivity, diminishing effect of antiplatelet drugs, as observed in ex-vivo assays; however, there have been no trials on dosing regimens and long-term outcomes regarding body mass index (BMI). Studies on NOAC reported little or no changes in the volume of distribution and half-life in obese patients, although they did not include patients with extreme obesity. Patients with BMI ≥35 kg/m2 treated with rivaroxaban had a reduced stroke risk compared with the rest of the cohort, and a similar trend was observed for apixaban in a subgroup with BMI ≥30 kg/m2 (31). Considering limited data on NOAC use in patients with extreme obesity (weight >120 kg or BMI ≥40 kg/m2), VKA might be considered the first option of treatment. NOAC plasma level measurement and dosage modification under the guidance of a hematologist for patients with extremely low and high body weight may be another option, although this approach has not been tested in long-term clinical studies (32). DAT and TAT should be individualized in this population due to limited data on combined therapy.
Chronic kidney disease
Chronic kidney disease (CKD) is characterized by an increased risk of thromboembolism and bleeding. The renal elimination varies between NOACs, with the lowest values for edoxaban and apixaban (27% and 35%, respectively). Apixaban, edoxaban and rivaroxaban are approved in Europe in patients with CKD and creatinine clearance (CrCl) of 15–29 mL/min in a reduced dose and contraindicated if CrCl is below 15 mL/min. In the retrospective analysis of RCTs comparing NOACs with VKA in AF patients, the efficacy and safety of NOACs were consistent across subgroups with mild to moderate CKD and without CKD (33). The bleeding benefit of NOAC over warfarin was observed for apixaban but not for dabigatran at lower CrCl values (27).
However, the landmark NOAC trials in AF patients undergoing PCI excluded patients with severe renal impairment (CrCl of <30 mL/min) and did not focus on other subgroups with CKD. In the PIONEER AF-PCI trial 27.9% of patients had CrCl of 30 to 60 ml/min and 0.8% had CrCl <30 mL/min (7). The AUGUSTUS trial included 8.4% patients with creatinine >1.5 mg/dL (9). Both studies showed the superiority of DAT in the reduction of bleeding complications and the same efficacy in thromboembolism prevention; however, the impact of kidney function on results was not analyzed. As the antiplatelet efficacy of aspirin is lower than clopidogrel, and its use in DAT and TAT increases major bleeding risk, clopidogrel should be administered as the single agent in combined antithrombotic therapy in patients with advanced CKD (34). DAT should be considered as an alternative in patients with mild-to-moderate CKD.
It is estimated that 5% of patients have or develop AF within the first months after diagnosis of cancer (35). Thromboembolic risk is increased in various types of cancer, with the greatest elevation in the pancreas, ovary, brain and lung cancers, and hematological neoplasms. Specific factors such as thrombocytopenia, neoplastic infiltration of arterial vessels, metastases, radiation therapy increase bleeding risk in cancer (36). AF patients with cancer belong to the group with very high bleeding risk, where TAT after PCI is rarely instituted, except subjects long-term after a few years of treatment, with good prognosis and without thrombocytopenia (37). Most centers, especially in the first weeks of cancer diagnosis, prefer DAT, i.e. clopidogrel with low-molecular-weight heparin or VKA. The duration of DAT is up to 12 months depending on the oncological status, thromboembolic and bleeding complications during therapy, and may be shortened to 1-6 months in the case of unacceptable bleeding (36). The 2019 ISTH guidelines on anticoagulation in patients with AF and cancer receiving chemotherapy recommend individualized anticoagulation, based on thrombotic/bleeding risk and patient preferences. The preference of NOACs over VKAs or heparins is suggested in patients with newly diagnosed AF, except for subjects with active duodenal ulcer, gastritis, esophagitis, colitis or with luminal GI cancer and an intact tumor (38).
Up to 3% of AF patients have thrombocytopenia defined as a platelet count below 100,000/µL (39). The PIONEER AF-PCI, RE-DUAL PCI and AUGUSTUS trial excluded patients with a platelet count below 90,000-100,000/µL, while ENTRUST-AF PCI excluded patients with severe thrombocytopenia (< 50,000/µL) (6–9). The current ESC guidelines do not provide any recommendations for the use of DAT and TAT in thrombocytopenic patients (2, 3). In recent studies, VKA in patients with moderate thrombocytopenia increased 3-fold the risk of minor bleedings (40). NOAC at reduced dose had acceptable safety and effectiveness in patients with a mean platelet count of 78,000 /µL (41). McCarthy et al. based on two RCTs with second-generation drug-eluting stents, where a subgroup of patients with moderate thrombocytopenia was enrolled, recommended shortening DAPT to one month after ACS, avoiding ticagrelor and prasugrel and avoiding TAT in subjects with indication to OAC (39). In patients with AF and platelet count <50,000/µL, the anticoagulation should be individualized given no evidence from randomized trials. Clopidogrel should be preferred in patients with severe thrombocytopenia.
The dual-therapy approach in AF patients undergoing PCI is now supported by current American and European guidelines. Summary of the current recommendations has been shown in Table 2 and 3.
Overall, dual antithrombotic therapy with NOAC and P2Y12 inhibitor (predominantly clopidogrel) is superior to triple therapy (VKA/NOAC + DAPT) in most patients with AF, as shown in RCTs. The excessive bleeding risk prevails benefit in reducing stent thrombosis. Current data suggest that a short course of TAT (e.g., 1 week) should be a default therapy for the majority of patients, followed by DAT for up to 12 months, and then with OAC only. Selected patients at high ischemic risk may benefit from a longer course of TAT. The duration of DAT and TAT can be modified based on a clinical setting (elective PCI vs ACS) and individual patient’s ischemic and bleeding risks. Individualized therapy in ACS and PCI patients who required anticoagulation should be considered in the presence of extreme ischemic or bleeding risks.
The study was supported by a grant of Jagiellonian University Medical College (N/41/DBS/000184, to A.U.).
Declaration of conflicting interests
AU received lecture honoraria from Bayer, Boehringer Ingelheim, and Pﬁzer. Other authors declare no conﬂict of interest.
AU, LD – the concept and design of the study, analysis and interpretation of data, revising the article for important intellectual content, final manuscript approval.
1. Crowther MA, Eikelboom JW. Dual and triple antithrombotic therapies: Current patterns of practice and controversies. Kardiol Pol 2018; 76: 937–44.
2. Knuuti J, Wijns W, Achenbach S, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41: 407–77.
3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 7: 2893–962.
4. Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy
and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381: 1107–15.
5. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774–82.
6. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394: 1335–43.
7. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–34.
8. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017;377: 1513–24.
9. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509–24.
10. Potpara TS, Mujovic N, Lip GYH. Meeting the unmet needs to
improve management and outcomes of patients with atrial fibrillation: Fitting global solutions to local settings. Polish Arch Intern Med. 2019; 129: 574–6.
11. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients
with atrial fibrillation: A meta-analysis of randomised trials. Lancet.
2014; 383: 955–62.
12. Liew A, O’Donnell M, Douketis J Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: A meta-analysis of randomized trials. J Thromb Haemost. 2014; 12: 1419–24.
13. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without
persistent ST-segment elevation of. Eur Heart J 2016; 37: 267–315.
14. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for
the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39: 119–77.
15. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardio-thoracic Surg 2018; 53: 34–78. doi: https://doi.org/10.1093/ejcts/ezx334
16. Bansilal S, Bonaca MP, Cornel JH, et al. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. J Am Coll Cardiol 2018; 71: 489–96.
17. Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent
implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol 2015; 65:1619–29.
18.*UDMHN62ODVLĔVND:LĞQLHZVND$0LFKDODN0HWDO7ULSOHYHUsus double antithrombotic therapy in patients with atrial fibrillation and stent implantation: A meta-analysis of randomized trials. Kardiol Pol 2019; 77: 837–45.
19. Lopes RD, Hong H, Harskamp RE, et al. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol 2019; 4: 747–55.
20. Lopes RD, Hong H, Harskamp RE, et al. Optimal Antithrombotic
Regimens for Patients With Atrial Fibrillation U ndergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol 2020; 5: 582–9.
21. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of non-Vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019; 40: 3757–67.
22. Potpara TS, Mujovic N, Proietti M, et al. Revisiting the Effects of Omitting Aspirin in Combined Antithrombotic Therapies for Atrial
Fibrillation and Acute Coronary Syndromes or Percutaneous Coronary Interventions: Meta-Analysis of Pooled Data From the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS Trial. Europace 2020; 22: 33–46.
23. Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med 2017; 377: 1580–2.
24. Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: A North American perspective-2018 update. Circulation 2018; 138: 527–36.
25. Sindet-Pedersen C, Lamberts M, Staerk L, et al. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. J Am Coll Cardiol 2018; 72(15): 1790–800.
26. Larsen TB, Potpara T, Dagres N, et al. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in
different clinical situations: Results of the European Heart Rhythm Association Survey. Europace 2015; 17: 819–24.
27. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial. Eur Heart J 2014; 35: 1864–72.
28. Sambola A, Mutuberría M, del Blanco BG, et al. Impact of triple therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention. PLoS One 2016; 11: 1–12.
29. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330–93.
30. Undas A, Drabik L, Potpara T. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. Polish Arch Intern Med 2020; 10.20452/pamw.15136.
31. Beavers CJ, Heron P, Smyth SS, et al. Obesity and AntiplateletsDoes One Size Fit All? Thromb Res 2015; 136: 712–6.
32. Tripodi A, Braham S, Scimeca B, et al. How and when to measure anticoagulant effects of direct oral anticoagulants? Practical
issues. Polish Arch Intern Med 2018; 128: 379–85.
33. Reinecke H, Engelbertz C, Schäbitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: Benefit
and risks of old and new oral anticoagulants. Stroke 2013; 44: 2935–41.
34. Covic A, Genovesi S, Rossignol P, et al. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med 2018; 16: 1–11.
35. Sanz AP, Gómez JLZ. AF in cancer patients: A different need for anticoagulation? Eur Cardiol Rev 2019; 14: 65–7.
36. Undas A, Drabik L. Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation. Anatol J Cardiol
37.Çetinkal G, Koçaş C, Koçaş BB, et al. Comparative performance of anTicoagulation and risk factors in atrial fibrillation and global registry of acute coronary events risk scores in predicting long-term adverse events in patients with acute myocardial infarction. Anatol J Cardiol 2018; 20: 77–84.
38. Delluc A, Wang TF, Yap ES, et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019; 17: 1247–52. doi: https://doi.org/10.1111/jth.14478
39. McCarthy CP, Steg GP, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum. Eur Heart J 2017; 38: 3488–92.
40. Lai YF, Goh DYT, How SY, et al. Safety and efficacy of warfarin in patients with moderate thrombocytopenia. Thromb Res 2017; 155:
41. Janion-Sadowska A, Papuga-Szela E, Lukaszuk R, et al. Non – Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia. J Cardiovasc Pharmacol 2018; 72: 153–60.